Literature DB >> 15823816

Peripheral primitive neuroectodermal tumor of the cerebellopontine angle.

Isam Alobid1, Felix Gastón, Antonio Morello, Jose María Guilemany, Joaquim Mullol.   

Abstract

Peripheral primitive neuroectodermal tumors are highly malignant small cell neoplasms. A 27-year-old female presented with a 6-month history of right-sided facial pain and progressive weakness of the facial muscles. She had non-pulsative tinnitus, progressive right hearing loss and facial palsy. T2-weighted MRI showed a heterogeneous hyperintense lesion invading the right internal auditory canal. Surgical removal was performed. Pathological examination showed sheets of small cells with irregular nuclei. Immunohistochemical studies demonstrated positive immunoreactivity for neuron-specific enolase, synaptophysin, chromogranin, vimentin, S-100 protein and p30-32 MIC-2 gene product. The patient was treated with chemotherapy (etoposide, vincristine, adriamycin, ifosfamide and actinomycin D) and radiotherapy. After 65 months of follow-up, the patient presented with cervical metastasis. Radical cervical dissection was performed and the patient was treated with a second course of chemotherapy. At control MRI after 29 months of follow-up the patient showed no signs of local recurrence or distant metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15823816     DOI: 10.1080/00016480410025234

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  2 in total

1.  Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor in the Cerebellopontine Angle : Diagnosis and Treatment.

Authors:  Ho Yong Choi; Yong Hwy Kim; Jee Hyun Kim; In Ah Kim; Gheeyoung Choe; Chae-Yong Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-06-30

2.  First description of a primitive neuroectodermal tumor arising in the nose.

Authors:  Habib Rizk; Aline Khazzaka; Amer Sebaaly; Maguy Cherfan; Roland Tomb; Riad Sarkis
Journal:  Case Rep Med       Date:  2013-05-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.